CG Oncology CFO Robert Lapetina resigns; Jim DeTore named interim CFO effective Nov 17, 2025

CG Oncology, Inc.

Robert Lapetina resigned as interim principal financial and accounting officer, effective Nov 30, 2025.
Jim DeTore appointed interim principal financial and accounting officer, effective Nov 17, 2025, via consulting agreement with Monomoy Advisors.
DeTore to receive $32K for November (prorated) and $64K/month thereafter; initial term min 3 months, extendable 3 months.
DeTore previously CFO at Neurogastrx (2021-2025) and Bluebird Bio (2014-2016); independent consultant 2017-2021.
No family relationships or conflicts disclosed; DeTore eligible for standard indemnification agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.